Alosetron

Placebo-controlled studies

In a 12-week placebo-controlled study of alosetron 0.5 mg/day, 1 mg/day, or 1 mg bd in 705 women with severe diarrhea-predominant irritable bowel syndrome, all doses of alosetron were effective [ ]. Constipation was the most common adverse event in the three dosage groups (9%, 16%, and 19% respectively). There was one case of intestinal obstruction and one of ischemic colitis with 0.5 mg/day and one case of fecal impaction with 1 mg bd. All were self-limited and resolved without sequelae.